Characterization of  isolates from Hebei, China: genotypes and drug susceptibility phenotypes by unknown
RESEARCH ARTICLE Open Access
Characterization of Mycobacterium
tuberculosis isolates from Hebei, China:
genotypes and drug susceptibility
phenotypes
Yanan Li1, Xinrui Cao2, Shiming Li3, Hao Wang4, Jianlin Wei5, Peng Liu6, Jing Wang7, Zhi Zhang1, Huixia Gao1,
Machao Li8, Kanglin Wan8 and Erhei Dai1*
Abstract
Background: Tuberculosis remains a major public health problem in China. The Hebei province is located in the
Beijing-Tianjin-Hebei integration region; however little information about the genetic diversity of Mycobacterium
tuberculosis was available in this area. This study describes the first attempt to map the molecular epidemiology of
MTB strains isolated from Hebei.
Methods: Spoligotyping and 15-locus MIRU-VNTR were performed in combination to yield specific genetic profiles
of 1017 MTB strains isolated from ten cities in the Hebei province in China during 2014. Susceptibility testing to first
line anti-TB drugs was also conducted for all strains using the L-J proportion method.
Results: Based on the SpolDB4.0 database, the predominant spoligotype belonged to the Beijing family (90.5 %),
followed by T family (6.3 %). Using 15-locus MIRU-VNTR clustering analysis, 846 different patterns were identified,
including 84 clusters (2–17 strains per cluster) and 764 individual types. Drug susceptibility pattern showed that
347 strains (34.1 %) were resistant to at least one of the first line drugs, including 134 (13.2 %) multi-drug resistance
strains. Statistical analysis indicated that drug resistance was associated with treatment history. The Beijing family
was associated with genetic clustering. However, no significant difference was observed between the Beijing and
non-Beijing family in gender, age, treatment history and drug resistance.
Conclusions: The Mycobacterium tuberculosis strains in Hebei exhibit high genetic diversity. The Beijing family is the
most prevalent lineage in this area. Spoligotyping in combination with 15-locus MIRU-VNTR is a useful tool to study
the molecular epidemiology of the MTB strains in Hebei.
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Background
Tuberculosis (TB) remains a major public health challenge
facing the world, second only to HIV/AIDS as the greatest
killer worldwide due to a single infectious agent. According
to a report from the World Health Organization (WHO),
approximately one-third of the world’s population has
latent TB [1, 2]. In 2013, 9 million people fell ill with TB
and 1.5 million died from this disease globally, with over
95 % of the TB deaths occurring in low- and middle-
income countries. China, the largest developing country,
has the second highest TB burden after India with 1.3
million TB patients and more than 0.8 million new cases in
2013. Approximately 5.7 % of new infections and 26 % of
retreated patients developed into multi-drug resistance TB
(MDR-TB) cases [2]. Despite the decrease in morbidity and
mortality rates, China still has a long way to go to control
TB due to the huge infected population base and the lack
of medical facilities and other social restrictions [3].
Developments in molecular epidemiology have allowed
rapid identification and tracking specific Mycobacterium
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tuberculosis (MTB) strains spreading through the popu-
lation. Insertion sequence (IS) ‘6110’ restricted fragment
length polymorphism (RFLP), which is the traditional
DNA fingerprinting method, is applied to genotype
MTB strains and has been utilized in TB outbreak inves-
tigation and long-term surveillance for over a decade.
However, its wide application is limited because of
labor-intensive procedures, demand on a technical level
and insufficient discrimination among strains with low
IS‘6110’ copy numbers (less than six) [4]. Therefore,
several PCR-based methods, such as spoligotyping and
MIRU-VNTR, have been well developed and widely used
for analyzing genetic diversity and population structure
of MTB strains due to the ease of result digitalization,
inter-laboratory comparison and data analysis. Spoligo-
typing, a secondary typing method for MTB strains, is
considered the gold standard for identifying Beijing
family MTB strains. However, its discriminatory power
is limited [5]. Mycobacterial interspersed repetitive
units-variable number of tandem repeats (MIRU-VNTR)
is based on PCR amplification of the interspersed repeti-
tive units to determine the size and repeated number of
each locus. It is a flexible approach, as sizing procedure
can be done by capillary [6], gel electrophoresis [7] or
nondenaturing high-performance liquid chromatography
[8]. Easy operation, digital database and high discrimin-
atory power make it an alternative method for RFLP [9].
Moreover, the combined application of MIRU-VNTR
and spoligotyping is increasingly common in MTB mo-
lecular epidemiology research [10, 11].
The Hebei province surrounds Beijing and Tianjin, and
its strategic position is significantly important due to the
development of economic integration of the Beijing-
Tianjin-Hebei integration region. The extensive and con-
venient traffic network makes Hebei a key transportation
hub connecting Beijing with the entire country. It covered
an area of 188,500 square kilometers with a population of
73.8 million in 2014. Based on the 2000 National TB
Epidemiology Survey in China, there were approximately
200,000 pulmonary TB patients in Hebei [12]. The TB
epidemic in Hebei leaves still little optimism, and the
population mobility and the spread of HIV makes the
situation even worse. Moreover, little information about
the genetic diversity of Mycobacterium tuberculosis in this
district is available to date. Therefore, this study aimed to
investigate the molecular epidemiological characteristics
and drug resistance status of clinical isolated TB strains in




The study contained 1017 MTB isolates, randomly col-
lected from 1017 sputum samples of 1017 patients, who
were clinically confirmed with pulmonary TB in hospi-
tals of infectious diseases in Hebei during 2014. All the
isolates were stored at −80 °C and recovered on the
Lowenstein-Jensen (L-J) medium at 37 °C for 4 weeks
when used. MTB H37Rv, kindly provided by China
Center for Disease Control and Prevention, was used as
the reference strain.
DNA extraction
Chromosomal DNA was extracted from mycobacterial
colonies grown on L-J medium using Mericon™ DNA
Bacteria Kit (Qiagen, USA) according to the manufac-
turer’s instructions. One loop of MTB colonies was resus-
pended in 200 μl fast lysis buffer by brief and vigorous
vortex, and then incubated at 100 °C for 10 min. After
centrifugation at 12,000 rpm for 5 min, the supernatant
containing DNA was collected and stored at −20 °C for
further use.
Drug susceptibility testing
The first line anti-TB drug susceptibility testing (DST)
was performed using the L-J proportion method, recom-
mended by WHO [13], at the Clinical Laboratory of the
Fifth Hospital of Shijiazhuang, China. The critical con-
centration were 0.2 μg/ml for isoniazid (INH), 40 μg/ml
for rifampicin (RIF), 4 μg/ml for streptomycin (STR) and
2 μg/ml for ethambutol (EMB). H37Rv strain was used
as a quality control and was tested each batch of DST.
The results were read 28 days after inoculation of the
strains. When the growth rate was more than 1 % com-
pared to the control, the strain was considered resistant
to the specific drug. Strains resistant to at least RIF and
INH were defined as MDR-TB.
Spoligotyping
Spoligotyping was performed using the standard proto-
col described by Kamerbeek et al. [14]. First, the direct
repeat (DR) region was amplified with primers of DRa
(biotin-labeled) and DRb. And then, the PCR products
were hybridized to a membrane with a set of 43 differ-
ent oligonucleotide probes covalently bound to the
surface. The results in binary format were compared
against the international spoligotype database SpolDB4.0
(http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/)
to obtain the spoligotyping pattern [15]. In this database,
Spoligotype International Type (SIT) designates an identi-
cal pattern shared by two or more patient isolates,
whereas orphan designates patterns reported for a single
isolate that does not correspond to any of the strains
recorded in the database repository [16].
MIRU-VNTR typing
The 15-locus MIRU-VNTR typing method, including
ETRA, ETRC, ETRD, ETRE, MIRU10, MIRU16, MIRU26,
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MIRU40, Mtub21, Mtub30, Mtub39, Mtub04, QUB11b,
QUB26 and QUB4156, was carried out to determine the
composition of each isolate [17]. First, the PCR amplifica-
tion of each locus was carried out individually using
primers in Additional file 1. Each PCR reaction contained
10 μl Taq MasterMix (CWBIO, China), 1 μl (10 μM)
forward primer, 1 μl (10 μM) reverse primer, 40-60 ng
of DNA template and double-distilled H2O to bring the
final volume to 20 μl. PCR was performed as follows:
initial denaturation at 94 °C for 5 min, and then 35 cy-
cles of denaturation at 94 °C for 30 s, annealing at 62 °C
for 30 s and extension at 72 °C for 45 s, with a final
extension at 72 °C for 10 min. Then, the PCR products
were electrophoresed on 1.5 % agarose gel and sized
with 100 bp DNA ladder (CWBIO, China). H37Rv was
used as positive control and double-distilled H2O was
used as negative control. The copy number of repeats
was calculated and entered into an Excel spreadsheet.
In addition, the Hunter-Gaston discriminatory Index
(HGDI) was used to evaluate the discriminatory power
of each locus.
Data management
Spoligotyping data in binary format and MIRU-VNTR data
in decimal format were analyzed using BioNumerics 5.0
software (Applied-Maths, Sint-Martens-Latem, Belgium).
Dendrogram and minimum spanning tree were generated
for clustering analysis. The discriminatory power and allelic
diversity of each locus were determined by Hunter-Gaston
discriminatory index (HGDI) value:






where N is the total number of strains in the typing
method, s is the total number of different patterns dis-
criminated by that method, and nj is the number of
strains belonging to the jth pattern. The HGDI value was
calculated using the discriminatory power calculator
available at http://www.hpa-bioinfotools.org.uk/cgi-bin/
DICI/DICI.pl [18]. The clustering rate was defined as
(nc−c)/N, where nc is the total number of clustered
strains, c is the number of clusters and N is the total
number of strains.
Statistical analysis
The statistical analysis was done by SPSS 16.0 software.
Chi-square test or Fisher’s exact probability test was used
to compare the proportions of different groups. Two-




A total of 1017 MTB strains collected from various re-
gions of the Hebei province during 2014 were enrolled in
this study, including 422 strains from Shijiazhuang, 149
from Cangzhou, 127 from Baoding, 125 from Xingtai, 90
from Tangshan, 79 from Qinhuangdao, 10 from Hengshui,
8 from Handan, 4 from Chengde, 3 from Langfang and
none from Zhangjiakou (Fig. 1). The enrolled patients
included 705 males (69.3 %) and 312 females (30.7 %),
with a median age of 38 (range from 11 to 89) years. The
anti-TB drug treatment history was available for 974
patients, including 753 new cases and 221 retreatment
patients. In addition, 493 of the new cases and 181 of the
retreatment patients were males.
Spoligotyping
Among the 1017 strains genotyped, 72 spoligotypes were
identified with the HGDI of 0.279. Of these, 57 spoligo-
types were previously represented in the SpolDB4.0
database, while the other 15 were not found in the
Fig. 1 Map of Hebei province showing the distribution of 1017
M. tuberculosis isolates enrolled in this study. The numbers represent
the population of isolates in particular regions'
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database and were marked as New genotypes. Out of
the 57 unique spoligotypes, 7 orphan spoligotypes were
identified, which referred to an isolate having a spoligo-
type that was present only once in the database. An
overview of New and orphan strains can be found in
Additional file 2.
The family assignment revealed that 920 strains (90.5 %)
belonged to the Beijing family, 97 (9.5 %) were from the
non-Beijing family. The non-Beijing family included 39
strains from the T1 family, 15 from the T2 family, 5 from
the T3 family, 1 from the T4 family, 1 from the T5 family,
1 from the LAM1 family, 3 from the LAM9 family, 7
from the MANU2 family, 7 from the H3 family, 1 from
the U family, 3 from the AMBIGOUS: T3 T2 family
and 14 from undefined family (Table 1). The clustering
analysis grouped 972 strains (95.6 %) into 27 clusters,
and the remaining 45 (4.4 %) were unique genotypes.
The largest cluster belonged to the typical Beijing family,
containing 863 strains (84.9 %) with the SIT number of 1,
characterized by the absence of the first 34 spacers and
the presence of spacers 35 to 43. The other 55 strains
(5.4 %) were defined as the atypical Beijing family for
missing one or more dots in spacers 35 to 43. Among 97
strains of the non-Beijing family, 20 with the SIT number
of 53 comprised the biggest cluster of the non-Beijing
family. The dendrogram also suggested that 2 of the
New genotypes were clustered into the atypical Beijing
family, and 13 were grouped into the non-Beijing family
(Additional file 3).
The minimum spanning tree was mapped to describe
the genetic links between the clusters using BioNumerics
5.0 software. Each node represented a particular genotype,
and the size of each node was determined by the number
of strains within that genotype [19]. As shown in Fig. 2,
the Beijing family and the non-Beijing family were classi-
fied into two large groups. The biggest cluster containing
863 strains (SIT1) belonged to the typical Beijing family
and was surrounded by small clusters of the atypical
Beijing family. The two larger clusters on the left were the
T1 and T2 family with the other non-Beijing family and
13 New genotypes around them. Particularly, 2 New geno-
typed strains were genetically close to the Beijing family
and the other 13 New genotypes were similar to the non-
Beijing family.
MIRU-VNTR typing
The 15-locus MIRU-VNTR clustering analysis divided
255 strains (25.1 %) into 84 clusters (2-17 strains per
cluster) and the remaining 762 (74.9 %) were individual
patterns. The clustering rate was 16.8 %. The clade
assignment showed that all the 1017 MTB strains were
clustered into 16 gene groups (Fig. 3). Groups I, II and
III shared similar MIRU-VNTR profiles, demonstrated
high homology with a close evolutionary distance and
belonged to the non-Beijing family according to spoligo-
typing. Group IV contained 17 individual genotypes, and
all of them are members of the Beijing family strains.
Group IV was closely related to Group V, the largest
clade, including 894 Beijing family isolates and 12 non-
Beijing family strains. There were 82 clusters in Group
V and the biggest cluster, which was composed of 16
Beijing family genotypes and 1 T1 strain, shared the
same MIRU-VNTR fingerprint, 643333564475493. One
Beijing family strain was classified into Group VI, as four
out of 15 loci were homologous with either Group V or
VII. Groups VII, VIII and IX contained 29 non-Beijing
family strains with similar MIRU-VNTR fingerprints and
close evolutionary distance. Among them, seven strains
belonged to T1, 14 to T2, 2 to MANU2, 2 to LAM9, 3
to New genotypes and 1 to an untitled family with a SIT
number of 2379. As the dendrogram showed that the
SIT2379 strain was genetically close to T2 family and
the 3 New genotypes shared high homology with T1 and
T2 family. The spoligotypes of Group X and XI belonged
to T1 family except 1 MANU2 family isolate. Group
XII ~ XV included seven individual Beijing family strains,
characterized by 2 ~ 4 loci absent and 6 ~ 9 loci identical
with strains in Group V. The independent New spoligo-
typed strain in Group XVI demonstrated a particular
MIRU-VNTR profile with little similarities to strains in
other groups.
The minimum spanning tree showed that the poly-
morphism of MTB isolates enrolled was intensively high
(Fig. 4). The largest cluster belonged to the Beijing geno-
type (light red and yellow) and was separated from the
non-Beijing family (green and blue). MIRU-VNTR can
separate the Beijing family into different small branches,
indicating that it possessed a higher discriminatory power
than spoligotyping.
The 15 MIRU-VNTR loci exhibited different HGDI
scores, ranging from 0.052 for ETRC to 0.722 for QUB11b.
Based on the HGDI values, the loci were further classified
into highly (>0.6), moderately (0.3-0.6) and poorly (<0.3)
discriminative loci [20, 21]. For all the strains, the HGDI of
2 loci (QUB11b and QUB26) were higher than 0.6, 7 loci
(QUB4156, ETRE, Mtub21, Mtub04, MIRU26, MIRU10
and ETRA) showed moderately discriminatory power and
the other 6 loci (MIRU40, MIRU16, Mtub39, Mtub30,
ETRD and ETRC) were found to be less discriminative
(Table 2). The discriminatory power (HGDI) of the total
loci set reached 0.999.
Drug resistance
The drug susceptibility testing showed that 670 isolates
(65.9 %) were sensitive to the four first-line anti-TB
drugs tested and 347 isolates (34.1 %) were resistant to
at least one of these drugs, including the 134 (13.2 %)
MDR strains. The drug resistance rates of STR, INH,
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Table 1 Spoligotypes of Mycobacterium tuberculosis strains in this study (n = 1017)
No. Spoligotype SITa Familyb N(%)c
1 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ 1 Beijing 863(84.9)
2 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■□■■■ 190 Beijing 18(1.8)
3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■□■■■■ 255 Beijing 2(0.2)
4 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■□□■■■■■ 260 Beijing 4(0.4)
5 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■□■■■■■■ 265 Beijing 3(0.3)
6 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■ 269 Beijing 6(0.6)
7 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□■■■ 406 Beijing 1(0.1)
8 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■□□■■ 541 Beijing 2(0.2)
9 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■□■■■■■■■ 621 Beijing 4(0.4)
10 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□■■■■■ 632 Beijing 2(0.2)
11 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■□■■ 941 Beijing 2(0.2)
12 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■□□□□ 1311 Beijing 2(0.2)
13 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□□■■■■ 1364 Beijing 1(0.1)
14 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■□■ 1674 Beijing 1(0.1)
15 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■□□□□□□□ 2101 Beijing 3(0.3)
16 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■□ 2610 Beijing 2(0.2)
17 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□□□■■■ Orphan Beijing 1(0.1)
18 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□■□■■■ Orphan Beijing 1(0.1)
19 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 53 T1 20(2.0)
20 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□■■■■■■ 240 T1 1(0.1)
21 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□■■ 956 T1 2(0.2)
22 ■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 334 T1 2(0.2)
23 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□□ 1793 T1 1(0.1)
24 ■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 498 T1 1(0.1)
25 ■■■■■■■■■■■■□□■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 131 T1 1(0.1)
26 ■■■■■■■■■■■■■■■■■■■□□□□□□■■■■■■■□□□□■■■■■■■ 1688 T1 1(0.1)
27 ■■■■■■■■■■■■■■■■■■■■□■■■■■■■■■■■□□□□■■■■■■■ 291 T1 1(0.1)
28 ■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■■■□□□□■■■■■■■ 1626 T1 1(0.1)
29 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■□□□□■■■■■■■ 462 T1 1(0.1)
30 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■□□□□□□□■■■■ Orphan T1 2(0.2)
31 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■□■■■■■ 520 T1 1(0.1)
32 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■□ 522 T1 3(0.3)
33 ■■■■■■□□□□□□□□□□□□■■■■■■■■■■■■■■□□□□■■■■■■■ 280 T1-RUS2 1(0.1)
34 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ 52 T2 9(0.9)
35 ■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ 848 T2 1(0.1)
36 □□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ 1613 T2 1(0.1)
37 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□■□■■■ Orphan T2 1(0.1)
38 ■■■■■■■■■■■■■■■■■■■■■■■□■■■■■■■■□□□□■■■□■■■ Orphan T2 1(0.1)
39 ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□■■□□□□■■■□■■■ 233 T2 2(0.2)
40 ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 37 T3 2(0.2)
41 ■□■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ Orphan T3 3(0.3)
42 ■■■■■■■■■■■■■■■■■■□■■■■■■■■■■■■■□□□□■■■■■■■ 40 T4 1(0.1)
43 ■■■■■■■■■■■■■■■■■■■■■■□■■■■■■■■■□□□□■■■■■■■ 44 T5 1(0.1)
44 ■□□□□□■■■■■■■■■■■■■■□□□□■■■■■■■■□□□□■■■■■■■ 961 LAM1 1(0.1)
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Table 1 Spoligotypes of Mycobacterium tuberculosis strains in this study (n = 1017) (Continued)
45 ■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■■□□□□■■■■■■■ 42 LAM9 1(0.1)
46 ■■■■■■■■■■■■■□□□□□□□□□□□■■■■■■■■□□□□■■■■■■■ 803 LAM9 1(0.1)
47 ■■■■■■■■■■■■■□□□□■□□□□□□■■■■■■■■□□□□■■■■■■■ 2191 LAM9 1(0.1)
48 ■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 2379 1(0.1)
49 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□■■■■■■■■■ 54 MANU2 4(0.4)
50 ■■■■■■■■■■■■■■■■■■■■□■■□■■■■■■■■□□■■■■■■■■■ 1523 MANU2 1(0.1)
51 ■■■■■■■■■■■■■■■■■■■■□■■■■■■■■■■■□□■■■■■■■■■ 1192 MANU2 2(0.2)
52 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ 50 H3 3(0.3)
53 ■■■■■■■■■■■■■■■■■■■■□■■■■■■■■■□■□□□□■■■■■■■ 268 H3 2(0.2)
54 ■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□■□□□□■■■■■■■ 791 H3 1(0.1)
55 ■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□■□□□□■■■■■■■ 1908 H3 1(0.1)
56 ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□□□■■■■■■■ 602 U 1(0.1)
57 ■□■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ Orphan AMBIGOUS:T3T2 3(0.3)
58 ■■■■■■■□■■■■■■■■□■■■□■■■■■■■■■■■□□■■■■■■■■■ - New 1(0.1)
59 ■■■■■■■■■■■■■■■■■■■■■■■■■□■■■■■■□□□□□□■■■■■ - New 1(0.1)
60 ■□□■■■□□■■■■■■■■■■■■■■■□□■■■□□□□□□■■□□□■□■■ - New 1(0.1)
61 ■■■■□■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□□□□□□ - New 1(0.1)
62 ■■■■■■■■■■■■□□■■■■■■■■■■■■■□■□■■□□■■■■■■■■■ - New 1(0.1)
63 □□□□■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□■■■□■■■ - New 1(0.1)
64 ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■□■■□□□□■■□■■■■ - New 1(0.1)
65 ■□■■■■■■■■■■□■■■□■■■■■■■■■■■■■■■□□□□■■■■■■■ - New 1(0.1)
66 ■□□□□□□■■■■□□■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ - New 1(0.1)
67 ■□■■■■■■■■■■□□□□■■■■■■■■■■■■■■■■□□□□■■□□■■■ - New 1(0.1)
68 ■□■■■■■■■■■■■■■■■■□■■□□□■■■■■■■■■■■■■■■□■■■ - New 1(0.1)
69 ■■■■■■□□□■■■■■■■■■■■■■□□□□□□□□□■□□□□■■■■■■■ - New 1(0.1)
70 ■■■■■■■■■■■■■■■■■■■■■■■■■■□□■■■□□□□□□□□■■■□ - New 1(0.1)
71 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■□■□■ - New 1(0.1)
72 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■□□□□□□ - New 1(0.1)
aSIT spoligotype international type
bSpoligotype families as assigned in SpolDB4.0
cThe number of the strains with a common SIT
Fig. 2 Minimum spanning tree showing the clustering analysis of 1017M. tuberculosis strains from Hebei by spoligotyping
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RIF, EMB were 24.9 % , 20.6 %, 17.9 % and 8.4 %, re-
spectively (Table 4). The total drug resistance rate of the
retreatment patients were significantly higher than that
of the initial treatments, and the same results were seen
in STR, INH, RIF and EMB mono-resistance rate and
MDR rate between the two groups (Table 3). However,
the Beijing and non-Beijing family had no statistical
associations in any drug resistance rates (Table 4).
Comparison of clinical factors and clustering
characteristics between the Beijing and non-Beijing family
Clinical factors, including age, gender and treatment his-
tory were analyzed between the Beijing and non-Beijing
family, but no statistical difference was found (Table 5).
In particular, compared to the initial treatment group,
men accounted for a significantly larger proportion of
the retreatment patients than women [p < 0.0001; OR
(95 %): 2.386 (1.642–3.469)]. The Beijing family strains
exhibited a significantly higher clustering rate than the
non-Beijing family strains by both spoligotyping and
MIRU-VNTR typing methods (Table 6).
Discussion
This is the first study on the genetic diversity of Mycobac-
terium tuberculosis strains in Hebei by two widely used
genotyping methods, spoligotyping and MIRU-VNTR typ-
ing. Our study found that the Beijing family is the pre-
dominant lineage of MTB strains in Hebei, lower than
that of Beijing (92.6 %) and Tianjin (91.7 %) [22, 23]. In
addition, non-Beijing family, including T1, T2, T3, T4,
T5, LAM1, LAM9, H3, U, MANU2, and AMBIGOUS:
T3 T2, demonstrated the genotypic polymorphisms of
MTB strains in Hebei. Based on the SpolDB4.0 database,
Fig. 3 Genotyping of 1017M. tuberculosis strains with MIRU-VNTR
and spoligotyping. From left to right: UPGMA dendrogram generated
by MIRU-VNTR, spoligotyping patterns, strain numbers, genetic lineage
based on SpolDB4.0
Fig. 4 Minimum spanning tree showing the clustering analysis of 1017M. tuberculosis strains from Hebei by MIRU-VNTR
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one strain with the SIT number of 2379, which was first
isolated from Belgium in 2004, belonged to an untitled
family. This is the first report that SIT2379 strain has been
isolated from China.
The Beijing family MTB strains have attracted world-
wide attention for their wide geographical distribution
and global emergence. This lineage has been reported to
be the most prominent clade in East Asia, China, Korea
and Japan, and also enjoyed popularity in Europe, Africa,
and North America [24–26]. The apparent global suc-
cess of the Beijing lineage suggested that it might have
selective advantages (higher virulence or transmissibility)
over other MTB genotypes. Additionally, it was hypothe-
sized that the Beijing family strains can escape from the
protection of BCG vaccine and the widespread of Beijing
genotype may result in the selective force of widely
BCG vaccination [27]. In our study, Beijing strains were
significantly associated with genotypic clustering, reflect-
ing recent transmission of this lineage in Hebei and con-
sistent with the former viewpoint.
Evidence has shown that the mutations in DNA repair
genes provided a selective advantage for Beijing geno-
type strains to acquire resistance to anti-TB drugs [28].
However, the association between the Beijing lineage
and drug resistance varied. In New York, Cuba, Estonia,
and Vietnam, the Beijing strains were strongly associated
with drug resistance, but elsewhere the association was
weak or absent [26]. Consistent with the latter, our find-
ing considered that the Beijing family genotypes were no
more likely to acquire drug resistance than the non-
Beijing genotypes. The results were probably biased by
the different proportion of Beijing subgroup in different
areas and the different ratios of ancient/modern Beijing
strains within different study population [29]. More de-
tailed studies on the drug resistance mechanisms of
particular genotype strains are of the utmost importance.
In addition, the statistical analysis demonstrated that the
Beijing and non-Beijing family exhibited no difference in
distribution of gender, age, and treatment history, indicat-
ing that other factors may contribute to the widespread of
the Beijing family strains.
In the present study, the drug resistance rate of the
retreatment patients was significantly higher than that of
new cases, indicating that improper use of TB antibi-
otics, including incorrect treatment regimens and poor
treatment compliance of TB patients, may result in drug
resistance. Advocating the rational use of anti-TB drugs
in clinical practice contributes to reduce the emergence
of drug resistant MTB strains.
A 70 % excess of male over female TB cases is reported
each year in the world [30]. It was reported that the global
male/female sex ratio was 1.96, with the highest being
4.93 in Russia and range of 0.8–1.13 observed in Central
America, Caribbean, Eastern Africa and Northern Europe
[31]. The male/female sex ratio in Hebei reached 2.26
Table 3 Drug susceptibility phenotypes of new cases and retreatments
DSTa N (%) New cases Retreatments OR (95 % CI)b p-value
Total 974 753 (77.3 %) 221 (22.7 %)
Pan sensitive 642 (65.9 %) 553 (86.1 %) 89 (13.9 %) 1 (Ref.)
Any resistancec 332 (34.1 %) 200 (60.2 %) 132 (39.8 %) 4.101 (2.996–5.613) <0.0001
Any S resistance 240 (24.6 %) 137 (57.1 %) 103 (42.9 %) 4.671 (3.325–6.562) <0.0001
Any H resistance 201 (20.6 %) 96 (47.8 %) 105 (52.2 %) 6.796 (4.760–9.703) <0.0001
Any R resistance 173 (17.8 %) 77 (44.5 %) 96 (55.5 %) 7.747 (5.328–11.26) <0.0001
Any E resistance 84 (8.6 %) 41 (48.8 %) 43 (51.2 %) 6.517 (4.020–10.56) <0.0001
MDRd 129 (13.2 %) 46 (35.7 %) 83 (64.3 %) 11.21 (7.335–17.14) <0.0001
aDST drug susceptibility testing
bOR odds ratio, CI confidence interval
cS streptomycin, H isoniazid, R rifampicin, E ethambutol
dMDR multi-drug resistance
Table 2 HGDI scores of the MIRU-VNTR loci for all the strains
Locus HGDI 95 % CI No. of alleles
QUB11b 0.722 0.714–0.730 12
QUB26 0.651 0.638–0.665 16
QUB4156 0.594 0.583–0.606 8
ETRE 0.592 0.579–0.605 10
Mtub21 0.555 0.539–0.570 11
Mtub04 0.554 0.539–0.568 9
MIRU26 0.547 0.531–0.563 12
MIRU10 0.407 0.391–0.424 8
ETRA 0.372 0.357–0.387 8
MIRU40 0.289 0.272–0.306 9
MIRU16 0.222 0.206–0.238 6
Mtub39 0.207 0.191–0.222 10
Mtub30 0.190 0.175–0.204 7
ETRD 0.171 0.156–0.186 10
ETRC 0.052 0.043–0.061 6
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(705/312), which is higher than the average level. A strong
opinion claimed the gender bias in TB infection, which
means that the prevalence of TB was higher in men than
in women [32]. In comparison to new cases, we found that
the proportion of males in the retreatment panel was
significantly larger than females. This suggested that men
were at a higher risk of TB recurrence. However, the
reason for this difference and the role of Y chromosome
on the susceptibility of MTB are still unclear.
Owing to the fairly low discriminatory power of spoli-
gotyping, 15 locus MIRU-VNTR was conducted for
further analysis. Data showed that the allelic diversity of
15 loci varied significantly, from 0.052 for ETRC to
0.722 for QUB11b, similar to the report from Inner
Mongolia [21]. The Beijing family strains with identical
MIRU-VNTR profiles were grouped into small branches,
but the non-Beijing family exhibited a high genetic di-
versity of MIRU-VNTR profiles, partly due to the small
population size. We hypothesized that the transmission
ability of the Beijing family was stronger than the non-
Beijing family in Hebei, but more epidemiology studies
are needed to confirm it.
Our study had some limitations. First, the number of
strains from Zhangjiakou, Chengde, Langfang, Hengshui
and Handan was quite small, because of no particular
TB laboratory in the local hospitals due to the poor
medical facilities and lack of technicians. Second, more
clinical factors needed to be collected and analyzed to
reveal the characteristics of different genotypes better.
Finally, mutations of drug resistance gene should be
detected to understand the genetic diversity of strains in
Hebei fully.
Conclusions
In summary, the MTB strains demonstrate high genetic
diversity and the predominant lineage is the Beijing family
in Hebei. The Beijing family is associated with genetic
clustering, but no correlation is observed with gender, age,
treatment history and drug resistance profiles. Spoligotyp-
ing in combination with 15-locus MIRU-VNTR is a useful
tool to study the molecular epidemiology of MTB strains






OR (95 % CI) p-value
Age, years
< 30 424 389 35 - 0.434
30–60 404 362 42
> 60 189 168 21
Gender
Male 705 632 73 1 0.204
Female 312 288 24 0.722 (0.446–1.168)
Treatment
history
New case 753 685 68 1 0.433
Retreatment 221 197 24 1.277 (0.751–2.007)
Table 4 Drug susceptibility phenotypes of the Beijing and non-Beijing family strains
DSTa N (%) Beijing, n (%) Non-Beijing, n (%) OR (95 % CI)b p-value
Total 1017 920 (90.5 %) 97 (9.5 %)
Pan sensitive 670 (65.9 %) 605 (90.3 %) 65(9.7 %) 1 (Ref.)
Any resistancec 347 (34.1 %) 315 (90.8 %) 32 (9.2 %) 0.946(0.606-1.475) 0.910
Any S resistance 253 (24.9 %) 229 (90.5 %) 24 (9.5 %) 0.976(0.596-1.596) 1.000
Any H resistance 210 (20.6 %) 191 (91.0 %) 19 (9.0 %) 0.926(0.541-1.583) 0.893
Any R resistance 182 (17.9 %) 169 (92.9 %) 13 (7.1 %) 0.716(0.385-1.330) 0.314
Any E resistance 85 (8.4 %) 75 (88.2 %) 10 (11.8 %) 1.241(0.611-2.519) 0.563
MDRd 134 (13.2 %) 123 (91.8 %) 11 (8.2 %) 0.832(0.427-1.623) 0.746
aDST drug susceptibility testing
bOR odds ratio, CI confidence interval
cS streptomycin, H isoniazid, R rifampicin, E ethambutol
dMDR multi-drug resistance
Table 6 Comparison of clustered and individual strains






Spoligotyping Individual strains, n 7 38
Clustered strains, n 913 59 <0.0001
Clusters, n 13 14
Clustering rate, % 97.8 46.4
MIRU-VNTR Individual strains, n 669 93
Clustered strains, n 251 4 <0.0001
Clusters, n 82 2
Clustering rate, % 18.4 2.1
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